Abstract

In the present work, the Bilayered matrix type tablet were prepared by direct and wet granulation technique, in which immediate release layer ( by direct compression) contains Nebivolol and extended release layer (by wet granulation) contains Nateglinide. All the developed bilayer tablets were evaluated for weight variation, friability, thickness and hardness. The percent deviation from the average weight, friability, thickness and hardness was found to be within the prescribed official limits. Release profile of Nebivolol from formulations indicate that lower MCC (Formulations CF1 and CF3) and lactose (Formulation CF3) content displayed higher release rates as compared to formulation with higher MCC and lactose content (Formulation CF2). Also the concentration of KYRON T-314 is also found to influence the release rate of the drug. It was found that formulation containing the highest concentration of superdisintegrants (Formulation CF3) has grater release then other subsequent formulations (Formulations CF1 and CF3). Similarly, the release profile of Nateglinide from formulations indicate that lower HPMC K15M (Formulation CF3) and lactose (Formulation CF3) content displayed higher release rates as compared to formulation with individual HPMC K15M, HPMC K100M, EC (Formulations CF1 and CF2) and higher lactose content (Formulations CF1 and CF2).

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.